Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near-Future Clinical Integration

Learn how experts apply practice-changing clinical data to integrate the use of BCMA-targeted agents for their patients with multiple myeloma with focused commentaries a healthcare professional resource and a module with downloadable slides.

Share

Program Content

Activities

Targeting BCMA in Multiple Myeloma: Module
Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near Future Clinical Integration
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 04, 2022

Expires: April 03, 2023

Activities

Targeting BCMA in Multiple Myeloma: Slides
Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near Future Clinical Integration
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 04, 2022

Expires: April 03, 2023

Activities

BCMA-Targeted Therapies for Multiple Myeloma
Current and Future Roles of BCMA-Targeted Therapies for Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2022

Expires: February 01, 2023

BCMA-Targeted Bispecific Antibodies in R/R MM
BCMA-Targeted Bispecific Antibodies: A New Approach for Relapsed/Refractory Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 14, 2022

Expires: April 13, 2023

Activities

BCMA-Targeted Therapies for R/R MM
Understanding BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2022

Expires: May 01, 2023

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.